A proteomic kinetic analysis of IGROV1 ovarian carcinoma cell line response to cisplatin treatment
- PMID: 17994630
- DOI: 10.1002/pmic.200700231
A proteomic kinetic analysis of IGROV1 ovarian carcinoma cell line response to cisplatin treatment
Abstract
Ovarian cancer is one of the leading causes of mortality by gynecological cancer. Despite good response to surgery and initial chemotherapy, essentially based on cisplatin (cis-diamino-dichloro-platinum(II) (CDDP)) compounds, frequent recurrences with chemoresistance acquisition are responsible for poor prognosis. Several mechanisms have been described as implicated in CDDP resistance, however they are not sufficient to exhaustively account for this resistance emergence. We applied a proteomic approach based on 2-DE coupled with MS (MALDI-TOF/TOF) to identify proteins associated with chemoresistance induced by CDDP. A kinetic analysis of IGROV1 cell behavior following treatment with CDDP and subsequent statistical analysis revealed time and/or concentration-dependent modifications in protein expression. We evidenced events such as decreased amino-acid and nucleotide synthesis potentially associated with cell cycle blockade, and variations that may be related to resistance acquisition, such as possible enhanced glycolysis and increased proliferating potential. Moreover, overexpressions of aldehyde dehydrogenase 1 and both cytokeratins 8 and 18 were consistent with our previous findings, demonstrating that expression of these proteins was increased in cisplatin-resistant IGROV1-R10 as compared to IGROV1 parental cells. Identification of such proteins could allow improved understanding of the mechanisms leading to cell death or survival and, thus, to the acquisition of chemoresistance.
Similar articles
-
Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10.Proteomics. 2006 Oct;6(19):5183-92. doi: 10.1002/pmic.200500925. Proteomics. 2006. PMID: 16941573
-
[Proteomic analysis of human ovarian cancer cell lines and their platinum-resistant clones].Zhonghua Fu Chan Ke Za Zhi. 2006 Sep;41(9):584-7. Zhonghua Fu Chan Ke Za Zhi. 2006. PMID: 17181965 Chinese.
-
Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines.J Proteome Res. 2007 Feb;6(2):772-80. doi: 10.1021/pr060402r. J Proteome Res. 2007. PMID: 17269733
-
Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.Gynecol Oncol. 2007 Apr;105(1):31-44. doi: 10.1016/j.ygyno.2006.12.011. Epub 2007 Feb 1. Gynecol Oncol. 2007. PMID: 17275076
-
Technology insight: the application of proteomics in gastrointestinal disease.Nat Clin Pract Gastroenterol Hepatol. 2007 Jul;4(7):372-85. doi: 10.1038/ncpgasthep0872. Nat Clin Pract Gastroenterol Hepatol. 2007. PMID: 17607293 Review.
Cited by
-
Proteomic approaches in understanding action mechanisms of metal-based anticancer drugs.Met Based Drugs. 2008;2008:716329. doi: 10.1155/2008/716329. Met Based Drugs. 2008. PMID: 18670610 Free PMC article.
-
Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation.Cell Death Dis. 2013 Oct 31;4(10):e887. doi: 10.1038/cddis.2013.384. Cell Death Dis. 2013. PMID: 24176845 Free PMC article.
-
Proteomics and ovarian cancer: integrating proteomics information into clinical care.J Proteomics. 2010 Sep 10;73(10):1864-72. doi: 10.1016/j.jprot.2010.05.013. Epub 2010 Jun 1. J Proteomics. 2010. PMID: 20561909 Free PMC article. Review.
-
Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers.OMICS. 2009 Aug;13(4):345-54. doi: 10.1089/omi.2009.0008. OMICS. 2009. PMID: 19422301 Free PMC article.
-
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.Mol Cancer Ther. 2010 Dec;9(12):3186-99. doi: 10.1158/1535-7163.MCT-10-0563. Epub 2010 Oct 1. Mol Cancer Ther. 2010. PMID: 20889728 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical